Pharmac Will Fund Any Medicine for Young People With Paediatric-Origin Cancers, About 15 a Year
The numbers are small, but the rule is unusual: New Zealand funds by tumour type and protocol rather than product by product.
The numbers are small, but the rule is unusual: New Zealand funds by tumour type and protocol rather than product by product.
A type II variation in Brussels does nothing directly for a child in Kinshasa. What it does is unlock the procurement channels that reach one.